Review



automated algorithm  (AliveCor Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    AliveCor Inc automated algorithm
    Automated Algorithm, supplied by AliveCor Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/automated+algorithm/automated+algorithms/pmc06423467-41-4-4
    Average 90 stars, based on 1 article reviews
    automated algorithm - by Bioz Stars, 2026-11
    90/100 stars

    Images

    Related Articles

    Selection:

    Article Title: 2021 ISHNE/HRS/EHRA/APHRS collaborative statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals
    Article Snippet: Several versions of the AliveCor’s automated algorithms have been evaluated, , , , , and the device has been tested as a screening tool in at‐risk populations., In Apple watch, the algorithm is effective when the heart rate is between 50 and 150 bpm, there are no or very few abnormal beats, and the shape, timing, and duration of each beat is considered normal for the patient (Figure ).

    Article Title: 2021 ISHNE/HRS/EHRA/APHRS Expert Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society
    Article Snippet: Several versions of the AliveCor’s automated algorithms have been evaluated (Chan 2016, Chan 2017, Desteghe 2017, Lowres 2014, Tarakji 2015), , – and the device has been tested as a screening tool in at-risk populations (Halcox 2017, Lowres 2014)., In Apple watch, the algorithm is effective when the heart rate (HR) is between 50 and 150 beats per minute; there are no or very few abnormal beats; and the shape, timing, and duration of each beat is considered normal for the patient (Figure ).

    Article Title: 2021 ISHNE/HRS/EHRA/APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals
    Article Snippet: Several versions of the AliveCor’s automated algorithms have been evaluated ( , , , , ), and the device has been tested as a screening tool in at-risk populations ( , ).

    Article Title: 2021 ISHNE/HRS/EHRA/APHRS Expert Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society
    Article Snippet: Several versions of the AliveCor’s automated algorithms have been evaluated (Chan 2016, Chan 2017, Desteghe 2017, Lowres 2014, Tarakji 2015), and the device has been tested as a screening tool in at-risk populations (Halcox 2017, Lowres 2014).

    Article Title: 2021 ISHNE/HRS/EHRA/APHRS Expert Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society
    Article Snippet: Several versions of the AliveCor’s automated algorithms have been evaluated ( Chan 2016, Chan 2017, Desteghe 2017, Lowres 2014, Tarakji 2015 ), and the device has been tested as a screening tool in at‐risk populations ( Halcox 2017, Lowres 2014 ).

    Article Title: 2021 ISHNE / HRS / EHRA / APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals
    Article Snippet: Several versions of the AliveCor’s automated algorithms have been evaluated ( , , , , ), and the device has been tested as a screening tool in at‐risk populations ( , ).

    Article Title: Diagnostic Performance of a Smart Device With Photoplethysmography Technology for Atrial Fibrillation Detection: Pilot Study (Pre-mAFA II Registry)
    Article Snippet: , 1013 patients , AliveCor automated algorithm , 71.4 , 99.4 , 76.9 , 99.2.

    Article Title: Study protocol for S martphone M onitoring for A trial fibrillation in R eal- T ime in India (SMART-India): a community-based screening and referral programme
    Article Snippet: In-field performance of AF-screening technology will be used by comparing results from the ANAND and AliveCor automated algorithms with the gold standard of adjudicated interpretations of the AliveCor ECG recordings.

    Sampling:

    Article Title: 2021 ISHNE/HRS/EHRA/APHRS collaborative statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals
    Article Snippet: Several versions of the AliveCor’s automated algorithms have been evaluated, , , , , and the device has been tested as a screening tool in at‐risk populations., In Apple watch, the algorithm is effective when the heart rate is between 50 and 150 bpm, there are no or very few abnormal beats, and the shape, timing, and duration of each beat is considered normal for the patient (Figure ).

    Article Title: 2021 ISHNE/HRS/EHRA/APHRS Expert Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society
    Article Snippet: Several versions of the AliveCor’s automated algorithms have been evaluated (Chan 2016, Chan 2017, Desteghe 2017, Lowres 2014, Tarakji 2015), , – and the device has been tested as a screening tool in at-risk populations (Halcox 2017, Lowres 2014)., In Apple watch, the algorithm is effective when the heart rate (HR) is between 50 and 150 beats per minute; there are no or very few abnormal beats; and the shape, timing, and duration of each beat is considered normal for the patient (Figure ).

    Article Title: 2021 ISHNE/HRS/EHRA/APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals
    Article Snippet: Several versions of the AliveCor’s automated algorithms have been evaluated ( , , , , ), and the device has been tested as a screening tool in at-risk populations ( , ).

    Article Title: 2021 ISHNE/HRS/EHRA/APHRS Expert Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society
    Article Snippet: Several versions of the AliveCor’s automated algorithms have been evaluated (Chan 2016, Chan 2017, Desteghe 2017, Lowres 2014, Tarakji 2015), and the device has been tested as a screening tool in at-risk populations (Halcox 2017, Lowres 2014).

    Article Title: 2021 ISHNE/HRS/EHRA/APHRS Expert Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society
    Article Snippet: Several versions of the AliveCor’s automated algorithms have been evaluated ( Chan 2016, Chan 2017, Desteghe 2017, Lowres 2014, Tarakji 2015 ), and the device has been tested as a screening tool in at‐risk populations ( Halcox 2017, Lowres 2014 ).

    Article Title: 2021 ISHNE / HRS / EHRA / APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals
    Article Snippet: Several versions of the AliveCor’s automated algorithms have been evaluated ( , , , , ), and the device has been tested as a screening tool in at‐risk populations ( , ).

    Article Title: Diagnostic Performance of a Smart Device With Photoplethysmography Technology for Atrial Fibrillation Detection: Pilot Study (Pre-mAFA II Registry)
    Article Snippet: , 1013 patients , AliveCor automated algorithm , 71.4 , 99.4 , 76.9 , 99.2.

    Article Title: Study protocol for S martphone M onitoring for A trial fibrillation in R eal- T ime in India (SMART-India): a community-based screening and referral programme
    Article Snippet: In-field performance of AF-screening technology will be used by comparing results from the ANAND and AliveCor automated algorithms with the gold standard of adjudicated interpretations of the AliveCor ECG recordings.

    Western Blot:

    Article Title: 2021 ISHNE/HRS/EHRA/APHRS collaborative statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals
    Article Snippet: Several versions of the AliveCor’s automated algorithms have been evaluated, , , , , and the device has been tested as a screening tool in at‐risk populations., In Apple watch, the algorithm is effective when the heart rate is between 50 and 150 bpm, there are no or very few abnormal beats, and the shape, timing, and duration of each beat is considered normal for the patient (Figure ).

    Article Title: 2021 ISHNE/HRS/EHRA/APHRS Expert Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society
    Article Snippet: Several versions of the AliveCor’s automated algorithms have been evaluated (Chan 2016, Chan 2017, Desteghe 2017, Lowres 2014, Tarakji 2015), , – and the device has been tested as a screening tool in at-risk populations (Halcox 2017, Lowres 2014)., In Apple watch, the algorithm is effective when the heart rate (HR) is between 50 and 150 beats per minute; there are no or very few abnormal beats; and the shape, timing, and duration of each beat is considered normal for the patient (Figure ).

    Article Title: 2021 ISHNE/HRS/EHRA/APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals
    Article Snippet: Several versions of the AliveCor’s automated algorithms have been evaluated ( , , , , ), and the device has been tested as a screening tool in at-risk populations ( , ).

    Article Title: 2021 ISHNE/HRS/EHRA/APHRS Expert Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society
    Article Snippet: Several versions of the AliveCor’s automated algorithms have been evaluated (Chan 2016, Chan 2017, Desteghe 2017, Lowres 2014, Tarakji 2015), and the device has been tested as a screening tool in at-risk populations (Halcox 2017, Lowres 2014).

    Article Title: 2021 ISHNE/HRS/EHRA/APHRS Expert Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society
    Article Snippet: Several versions of the AliveCor’s automated algorithms have been evaluated ( Chan 2016, Chan 2017, Desteghe 2017, Lowres 2014, Tarakji 2015 ), and the device has been tested as a screening tool in at‐risk populations ( Halcox 2017, Lowres 2014 ).

    Article Title: 2021 ISHNE / HRS / EHRA / APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals
    Article Snippet: Several versions of the AliveCor’s automated algorithms have been evaluated ( , , , , ), and the device has been tested as a screening tool in at‐risk populations ( , ).

    Article Title: Diagnostic Performance of a Smart Device With Photoplethysmography Technology for Atrial Fibrillation Detection: Pilot Study (Pre-mAFA II Registry)
    Article Snippet: , 1013 patients , AliveCor automated algorithm , 71.4 , 99.4 , 76.9 , 99.2.

    Article Title: Study protocol for S martphone M onitoring for A trial fibrillation in R eal- T ime in India (SMART-India): a community-based screening and referral programme
    Article Snippet: In-field performance of AF-screening technology will be used by comparing results from the ANAND and AliveCor automated algorithms with the gold standard of adjudicated interpretations of the AliveCor ECG recordings.

    Biomarker Discovery:

    Article Title: 2021 ISHNE/HRS/EHRA/APHRS collaborative statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals
    Article Snippet: Several versions of the AliveCor’s automated algorithms have been evaluated, , , , , and the device has been tested as a screening tool in at‐risk populations., In Apple watch, the algorithm is effective when the heart rate is between 50 and 150 bpm, there are no or very few abnormal beats, and the shape, timing, and duration of each beat is considered normal for the patient (Figure ).

    Article Title: 2021 ISHNE/HRS/EHRA/APHRS Expert Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society
    Article Snippet: Several versions of the AliveCor’s automated algorithms have been evaluated (Chan 2016, Chan 2017, Desteghe 2017, Lowres 2014, Tarakji 2015), , – and the device has been tested as a screening tool in at-risk populations (Halcox 2017, Lowres 2014)., In Apple watch, the algorithm is effective when the heart rate (HR) is between 50 and 150 beats per minute; there are no or very few abnormal beats; and the shape, timing, and duration of each beat is considered normal for the patient (Figure ).

    Article Title: 2021 ISHNE/HRS/EHRA/APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals
    Article Snippet: Several versions of the AliveCor’s automated algorithms have been evaluated ( , , , , ), and the device has been tested as a screening tool in at-risk populations ( , ).

    Article Title: 2021 ISHNE/HRS/EHRA/APHRS Expert Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society
    Article Snippet: Several versions of the AliveCor’s automated algorithms have been evaluated (Chan 2016, Chan 2017, Desteghe 2017, Lowres 2014, Tarakji 2015), and the device has been tested as a screening tool in at-risk populations (Halcox 2017, Lowres 2014).

    Article Title: 2021 ISHNE/HRS/EHRA/APHRS Expert Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society
    Article Snippet: Several versions of the AliveCor’s automated algorithms have been evaluated ( Chan 2016, Chan 2017, Desteghe 2017, Lowres 2014, Tarakji 2015 ), and the device has been tested as a screening tool in at‐risk populations ( Halcox 2017, Lowres 2014 ).

    Article Title: 2021 ISHNE / HRS / EHRA / APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals
    Article Snippet: Several versions of the AliveCor’s automated algorithms have been evaluated ( , , , , ), and the device has been tested as a screening tool in at‐risk populations ( , ).

    Article Title: Diagnostic Performance of a Smart Device With Photoplethysmography Technology for Atrial Fibrillation Detection: Pilot Study (Pre-mAFA II Registry)
    Article Snippet: , 1013 patients , AliveCor automated algorithm , 71.4 , 99.4 , 76.9 , 99.2.

    Article Title: Study protocol for S martphone M onitoring for A trial fibrillation in R eal- T ime in India (SMART-India): a community-based screening and referral programme
    Article Snippet: In-field performance of AF-screening technology will be used by comparing results from the ANAND and AliveCor automated algorithms with the gold standard of adjudicated interpretations of the AliveCor ECG recordings.



    Similar Products

    incucyte automated angiogenesis algorithm  (Sartorius AG)
    99
    Sartorius AG incucyte automated angiogenesis algorithm
    <t>Angiogenesis</t> induced by VEGF secreted from VEGF-MSCs. Human umbilical vein endothelial cells labelled by CytoLight Green (GFP-HUVECs) were used for the development of angiogenic networks, and the length of networks was determined by the <t>IncuCyte</t> live-cell analysis system. ( A ) VEGF effectively induced the formation of vascular networks, which was able to be inhibited by suramin, a VEGF signaling inhibitor. Data shown as mean (SD) ( n = 6). ( B ) A concentration-dependent effect was shown in the angiogenesis assay using CCM-VEGF with different VEGF concentrations (1, 2, 4, and 8 ng/mL). Blank control, without any VEGF supplement added; suramin group, 4 ng/mL VEGF and 100 µM suramin added. Data shown as mean (SD) ( n = 4); ns, not significant; **** p < 0.05.
    Incucyte Automated Angiogenesis Algorithm, supplied by Sartorius AG, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/automated+algorithm/Live+Cell+Analysis+Instruments/pmc13115070-94-6-13
    Average 99 stars, based on 1 article reviews
    incucyte automated angiogenesis algorithm - by Bioz Stars, 2026-11
    99/100 stars
    		  Buy from Supplier
    neonatal automated seizure detection algorithm  (Persyst Development Corporation)
    86
    Persyst Development Corporation neonatal automated seizure detection algorithm
    <t>Angiogenesis</t> induced by VEGF secreted from VEGF-MSCs. Human umbilical vein endothelial cells labelled by CytoLight Green (GFP-HUVECs) were used for the development of angiogenic networks, and the length of networks was determined by the <t>IncuCyte</t> live-cell analysis system. ( A ) VEGF effectively induced the formation of vascular networks, which was able to be inhibited by suramin, a VEGF signaling inhibitor. Data shown as mean (SD) ( n = 6). ( B ) A concentration-dependent effect was shown in the angiogenesis assay using CCM-VEGF with different VEGF concentrations (1, 2, 4, and 8 ng/mL). Blank control, without any VEGF supplement added; suramin group, 4 ng/mL VEGF and 100 µM suramin added. Data shown as mean (SD) ( n = 4); ns, not significant; **** p < 0.05.
    Neonatal Automated Seizure Detection Algorithm, supplied by Persyst Development Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/automated+algorithm/algorithm+automated+detection+neonatal+seizure/pmc13172172-88-25-24
    Average 86 stars, based on 1 article reviews
    neonatal automated seizure detection algorithm - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    phillips respironics automated activity based sleep algorithm  (Respironics)
    86
    Respironics phillips respironics automated activity based sleep algorithm
    <t>Angiogenesis</t> induced by VEGF secreted from VEGF-MSCs. Human umbilical vein endothelial cells labelled by CytoLight Green (GFP-HUVECs) were used for the development of angiogenic networks, and the length of networks was determined by the <t>IncuCyte</t> live-cell analysis system. ( A ) VEGF effectively induced the formation of vascular networks, which was able to be inhibited by suramin, a VEGF signaling inhibitor. Data shown as mean (SD) ( n = 6). ( B ) A concentration-dependent effect was shown in the angiogenesis assay using CCM-VEGF with different VEGF concentrations (1, 2, 4, and 8 ng/mL). Blank control, without any VEGF supplement added; suramin group, 4 ng/mL VEGF and 100 µM suramin added. Data shown as mean (SD) ( n = 4); ns, not significant; **** p < 0.05.
    Phillips Respironics Automated Activity Based Sleep Algorithm, supplied by Respironics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/automated+algorithm/activity+algorithm+automated+based+phillips+respironics+sleep/med_rxiv__64898__2026__03__05__26347744-36-28-28
    Average 86 stars, based on 1 article reviews
    phillips respironics automated activity based sleep algorithm - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    algorithms flowlogic  (Bio-Rad)
    97
    Bio-Rad algorithms flowlogic
    <t>Angiogenesis</t> induced by VEGF secreted from VEGF-MSCs. Human umbilical vein endothelial cells labelled by CytoLight Green (GFP-HUVECs) were used for the development of angiogenic networks, and the length of networks was determined by the <t>IncuCyte</t> live-cell analysis system. ( A ) VEGF effectively induced the formation of vascular networks, which was able to be inhibited by suramin, a VEGF signaling inhibitor. Data shown as mean (SD) ( n = 6). ( B ) A concentration-dependent effect was shown in the angiogenesis assay using CCM-VEGF with different VEGF concentrations (1, 2, 4, and 8 ng/mL). Blank control, without any VEGF supplement added; suramin group, 4 ng/mL VEGF and 100 µM suramin added. Data shown as mean (SD) ( n = 4); ns, not significant; **** p < 0.05.
    Algorithms Flowlogic, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/automated+algorithm/TC20+Automated+Cell+Counter/pm40674218-46-127-137
    Average 97 stars, based on 1 article reviews
    algorithms flowlogic - by Bioz Stars, 2026-11
    97/100 stars
    		  Buy from Supplier
    automated edge-detection algorithm qangio xa 7.3  (Medis)
    90
    Medis automated edge-detection algorithm qangio xa 7.3
    <t>Angiogenesis</t> induced by VEGF secreted from VEGF-MSCs. Human umbilical vein endothelial cells labelled by CytoLight Green (GFP-HUVECs) were used for the development of angiogenic networks, and the length of networks was determined by the <t>IncuCyte</t> live-cell analysis system. ( A ) VEGF effectively induced the formation of vascular networks, which was able to be inhibited by suramin, a VEGF signaling inhibitor. Data shown as mean (SD) ( n = 6). ( B ) A concentration-dependent effect was shown in the angiogenesis assay using CCM-VEGF with different VEGF concentrations (1, 2, 4, and 8 ng/mL). Blank control, without any VEGF supplement added; suramin group, 4 ng/mL VEGF and 100 µM suramin added. Data shown as mean (SD) ( n = 4); ns, not significant; **** p < 0.05.
    Automated Edge Detection Algorithm Qangio Xa 7.3, supplied by Medis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/automated+algorithm/computer+assisted++automated+edge+detection+algorithm+qangio+xa/pm40503438-67-3-8
    Average 90 stars, based on 1 article reviews
    automated edge-detection algorithm qangio xa 7.3 - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    neuroguide's automated artifact rejection algorithm  (Applied Neuroscience Inc)
    90
    Applied Neuroscience Inc neuroguide's automated artifact rejection algorithm
    <t>Angiogenesis</t> induced by VEGF secreted from VEGF-MSCs. Human umbilical vein endothelial cells labelled by CytoLight Green (GFP-HUVECs) were used for the development of angiogenic networks, and the length of networks was determined by the <t>IncuCyte</t> live-cell analysis system. ( A ) VEGF effectively induced the formation of vascular networks, which was able to be inhibited by suramin, a VEGF signaling inhibitor. Data shown as mean (SD) ( n = 6). ( B ) A concentration-dependent effect was shown in the angiogenesis assay using CCM-VEGF with different VEGF concentrations (1, 2, 4, and 8 ng/mL). Blank control, without any VEGF supplement added; suramin group, 4 ng/mL VEGF and 100 µM suramin added. Data shown as mean (SD) ( n = 4); ns, not significant; **** p < 0.05.
    Neuroguide's Automated Artifact Rejection Algorithm, supplied by Applied Neuroscience Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/automated+algorithm/neuroguide+s+automated+artifact+rejection+algorithm/pmc12282553-80-8-5
    Average 90 stars, based on 1 article reviews
    neuroguide's automated artifact rejection algorithm - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    automated artifact rejection algorithm  (MathWorks Inc)
    90
    MathWorks Inc automated artifact rejection algorithm
    <t>Angiogenesis</t> induced by VEGF secreted from VEGF-MSCs. Human umbilical vein endothelial cells labelled by CytoLight Green (GFP-HUVECs) were used for the development of angiogenic networks, and the length of networks was determined by the <t>IncuCyte</t> live-cell analysis system. ( A ) VEGF effectively induced the formation of vascular networks, which was able to be inhibited by suramin, a VEGF signaling inhibitor. Data shown as mean (SD) ( n = 6). ( B ) A concentration-dependent effect was shown in the angiogenesis assay using CCM-VEGF with different VEGF concentrations (1, 2, 4, and 8 ng/mL). Blank control, without any VEGF supplement added; suramin group, 4 ng/mL VEGF and 100 µM suramin added. Data shown as mean (SD) ( n = 4); ns, not significant; **** p < 0.05.
    Automated Artifact Rejection Algorithm, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/automated+algorithm/pmc12152602-401-12-17
    Average 90 stars, based on 1 article reviews
    automated artifact rejection algorithm - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    algorithms imagexpress micro xl ixm automated imaging system molecular devices  (Danaher Inc)
    96
    Danaher Inc algorithms imagexpress micro xl ixm automated imaging system molecular devices
    <t>Angiogenesis</t> induced by VEGF secreted from VEGF-MSCs. Human umbilical vein endothelial cells labelled by CytoLight Green (GFP-HUVECs) were used for the development of angiogenic networks, and the length of networks was determined by the <t>IncuCyte</t> live-cell analysis system. ( A ) VEGF effectively induced the formation of vascular networks, which was able to be inhibited by suramin, a VEGF signaling inhibitor. Data shown as mean (SD) ( n = 6). ( B ) A concentration-dependent effect was shown in the angiogenesis assay using CCM-VEGF with different VEGF concentrations (1, 2, 4, and 8 ng/mL). Blank control, without any VEGF supplement added; suramin group, 4 ng/mL VEGF and 100 µM suramin added. Data shown as mean (SD) ( n = 4); ns, not significant; **** p < 0.05.
    Algorithms Imagexpress Micro Xl Ixm Automated Imaging System Molecular Devices, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/automated+algorithm/ImageXpress+Micro+Confocal+High-Content+Imaging+System/10__1016_slash_j__isci__2025__112501-239-181-188
    Average 96 stars, based on 1 article reviews
    algorithms imagexpress micro xl ixm automated imaging system molecular devices - by Bioz Stars, 2026-11
    96/100 stars
    		  Buy from Supplier
    automated edge detection algorithm  (Medis)
    86
    Medis automated edge detection algorithm
    <t>Angiogenesis</t> induced by VEGF secreted from VEGF-MSCs. Human umbilical vein endothelial cells labelled by CytoLight Green (GFP-HUVECs) were used for the development of angiogenic networks, and the length of networks was determined by the <t>IncuCyte</t> live-cell analysis system. ( A ) VEGF effectively induced the formation of vascular networks, which was able to be inhibited by suramin, a VEGF signaling inhibitor. Data shown as mean (SD) ( n = 6). ( B ) A concentration-dependent effect was shown in the angiogenesis assay using CCM-VEGF with different VEGF concentrations (1, 2, 4, and 8 ng/mL). Blank control, without any VEGF supplement added; suramin group, 4 ng/mL VEGF and 100 µM suramin added. Data shown as mean (SD) ( n = 4); ns, not significant; **** p < 0.05.
    Automated Edge Detection Algorithm, supplied by Medis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/automated+algorithm/algorithm+automated+detection+edge/pm40436465-47-24-31
    Average 86 stars, based on 1 article reviews
    automated edge detection algorithm - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    automated monitoring and thyroid disease diagnosis algorithms  (Diabetology)
    90
    Diabetology automated monitoring and thyroid disease diagnosis algorithms
    <t>Angiogenesis</t> induced by VEGF secreted from VEGF-MSCs. Human umbilical vein endothelial cells labelled by CytoLight Green (GFP-HUVECs) were used for the development of angiogenic networks, and the length of networks was determined by the <t>IncuCyte</t> live-cell analysis system. ( A ) VEGF effectively induced the formation of vascular networks, which was able to be inhibited by suramin, a VEGF signaling inhibitor. Data shown as mean (SD) ( n = 6). ( B ) A concentration-dependent effect was shown in the angiogenesis assay using CCM-VEGF with different VEGF concentrations (1, 2, 4, and 8 ng/mL). Blank control, without any VEGF supplement added; suramin group, 4 ng/mL VEGF and 100 µM suramin added. Data shown as mean (SD) ( n = 4); ns, not significant; **** p < 0.05.
    Automated Monitoring And Thyroid Disease Diagnosis Algorithms, supplied by Diabetology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/automated+algorithm/thyroid+diseases/pmc12154553-24-15-10
    Average 90 stars, based on 1 article reviews
    automated monitoring and thyroid disease diagnosis algorithms - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Angiogenesis induced by VEGF secreted from VEGF-MSCs. Human umbilical vein endothelial cells labelled by CytoLight Green (GFP-HUVECs) were used for the development of angiogenic networks, and the length of networks was determined by the IncuCyte live-cell analysis system. ( A ) VEGF effectively induced the formation of vascular networks, which was able to be inhibited by suramin, a VEGF signaling inhibitor. Data shown as mean (SD) ( n = 6). ( B ) A concentration-dependent effect was shown in the angiogenesis assay using CCM-VEGF with different VEGF concentrations (1, 2, 4, and 8 ng/mL). Blank control, without any VEGF supplement added; suramin group, 4 ng/mL VEGF and 100 µM suramin added. Data shown as mean (SD) ( n = 4); ns, not significant; **** p < 0.05.

    Journal: Cells

    Article Title: Extracellular Vesicles Derived from VEGF mRNA-Engineered Mesenchymal Stem Cells Promote Endothelial Cell Survival

    doi: 10.3390/cells15080717

    Figure Lengend Snippet: Angiogenesis induced by VEGF secreted from VEGF-MSCs. Human umbilical vein endothelial cells labelled by CytoLight Green (GFP-HUVECs) were used for the development of angiogenic networks, and the length of networks was determined by the IncuCyte live-cell analysis system. ( A ) VEGF effectively induced the formation of vascular networks, which was able to be inhibited by suramin, a VEGF signaling inhibitor. Data shown as mean (SD) ( n = 6). ( B ) A concentration-dependent effect was shown in the angiogenesis assay using CCM-VEGF with different VEGF concentrations (1, 2, 4, and 8 ng/mL). Blank control, without any VEGF supplement added; suramin group, 4 ng/mL VEGF and 100 µM suramin added. Data shown as mean (SD) ( n = 4); ns, not significant; **** p < 0.05.

    Article Snippet: Image analysis was performed using the IncuCyte automated angiogenesis algorithm (Incucyte software, v2024B, Sartorius).

    Techniques: Cell Analysis, Concentration Assay, Angiogenesis Assay, Control